A signal from inside your cells.
MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a peptide encoded within mitochondrial DNA — specifically in the 12S rRNA gene. It's one of a small class of peptides now called mitochondria-derived peptides (MDPs), which are signaling molecules your mitochondria produce in response to cellular stress.
MOTS-c acts on AMPK (AMP-activated protein kinase), which is a key regulator of cellular energy balance. When AMPK is activated, it promotes fat oxidation, inhibits fat synthesis, enhances glucose uptake in muscle tissue, and improves mitochondrial function. Think of AMPK activation as flipping your cells into "efficient energy mode."
MOTS-c levels decline with age and are associated with metabolic health markers. Research has shown it can improve insulin sensitivity, reduce metabolic syndrome features, and enhance physical performance through better cellular energy utilization.
For patients who want mitochondrial performance.
MOTS-c is best suited for patients focused on energy, metabolic flexibility, and physical performance — people who want their cells to work better, not just their hormones to look better on paper.
It's often used as part of broader longevity and performance protocols, sometimes alongside NAD+ (which supports mitochondrial energy production through a different mechanism) or GH peptides.
- Metabolic flexibility and energy efficiency
- Improved insulin sensitivity
- Physical performance enhancement
- Age-related metabolic decline
- Mitochondrial function support
- Body composition through metabolic optimization
A cellular-level performance protocol.
MOTS-c is administered via subcutaneous injection, typically 2–5 times per week depending on the protocol design. Exercise timing has been studied — some research suggests administration close to workout sessions may amplify the performance-related effects.
Cycles of 8–12 weeks with breaks are the typical approach. This is a relatively newer peptide in clinical use, and protocols are still being refined based on accumulating clinical experience.
| Goal | Frequency | Timing |
|---|---|---|
| Metabolic support | 2–3x weekly | Morning or pre-exercise |
| Performance | 4–5x weekly | Pre-exercise preferred |
| Longevity protocol | 2–3x weekly | Flexible |
What you should know
MOTS-c has a favorable tolerability profile based on current clinical experience. Injection site reactions are the most commonly reported side effect. No significant systemic side effects have emerged in clinical use to date.
As a relatively newer therapeutic, the long-term safety data in humans is still accumulating. We're transparent about this with patients and discuss it as part of informed consent.
Common questions about MOTS-c
They work through different mechanisms and are often complementary. NAD+ supports the mitochondrial machinery that produces energy (the electron transport chain). MOTS-c activates AMPK signaling that regulates how cells use and distribute energy. Many longevity protocols include both.
Yes, though the evidence base is earlier-stage than for peptides like semaglutide or BPC-157. MOTS-c was first described in human biology in 2015. Research into its metabolic effects and exercise performance implications is active and growing.
The current evidence suggests there may be a synergistic relationship between MOTS-c and exercise — some research indicates that exercise amplifies the signaling effects of MOTS-c administration. We discuss training context as part of the protocol design.
We review your labs, goals, and health history before recommending any protocol. Available in-person in St. Louis or via secure telehealth.
📅 Request a Consultation →